Raíza Alves-Pereira, Mariana Fontes, Vivian Cordeiro, Igor D Bandeira, Daniela Faria-Guimarães, Samantha S Silva, Rodrigo P Mello, Gustavo C Leal, Aline S Sampaio, Lucas C Quarantini
OBJECTIVE: Converging evidence supports the role of the glutamate, an excitatory amino acid neurotransmitter, in the pathophysiology of obsessive-compulsive disorder (OCD). Ketamine and esketamine, both noncompetitive N-methyl-d-aspartate antagonists, have emerged as a promising medication for this psychiatric disorder, given its possible efficacy with faster onset and good tolerability. The purpose of this retrospective chart review is to evaluate whether unbiased clinical documentation supports formal clinical trials of esketamine for an OCD indication...
January 2, 2024: Clinical Neuropharmacology